CAI Q1 2026 Earnings Call Summary

Summary of Caris Life Sciences, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: $216 million, a 79% increase year-over-year.
Molecular Profiling Services Revenue: $211 million, up 85% year-over-year.
Clinical Case Volume: 52,800 completed cases, a 15% increase year-over-year.
Average Selling Price (ASP): Increased by 61%, with tissue ASP at over $4,300 and blood ASP just under $2,500.
Gross Margin: 65%, up from 47% in Q1 2025.
Adjusted EBITDA: Positive $26 million, marking the fourth consecutive quarter of positive adjusted EBITDA.
Free Cash Flow: Positive $22.5 million.
Cash on Hand: Increased to over $825 million.

2. Strategic Updates and Business Highlights

Sales Team Realignment: Expanded territory structure from 82 to 146 territories, leading to improved coverage and accountability.
Product Launches:
- Caris ChromaSeq: Launched on April 1, a therapy selection assay for hematological cancers.
- Caris MI Clarity: A prognostic test for breast cancer.
Multi-Cancer Early Detection (MCED): Progressing towards commercial launch with Everlywell, with plans to expand channel partners.
Precision Oncology Alliance: Added UC San Francisco as the 100th member, enhancing collaboration and data sharing.

3. Forward Guidance and Outlook

Volume Growth Expectations:
- Tissue growth projected in the low teens.
- Blood growth expected in the high 50s to low 60s.
Q2 Revenue Guidance: Anticipated growth of approximately 32%.
Q2 Volume Expectations: Targeting over 58,000 completed cases, with a 10% sequential growth from Q1.
Pipeline Contributions: Evaluation of contributions from new product launches (ChromaSeq and MI Clarity) to be assessed post-Q2.

4. Bad News, Challenges, or Points of Concern

Initial Volume Performance: Q1 volumes were slightly below expectations due to timing issues related to the sales realignment.
Pharma and Research Revenue Decline: Revenue decreased to $5.4 million from $6.8 million in Q1 2025, attributed to contract deliverable movements.
Reimbursement Risks: Concerns surrounding reimbursement pressures in the industry, although management expressed confidence in their CDLT status and PAMA submission.
Market Competition: Competitive pressures in the liquid biopsy space, with ongoing scrutiny regarding reimbursement frameworks.

5. Notable Q&A Insights

Sales Realignment Impact: Management acknowledged a slower start due to the sales realignment but noted improved performance in February and March.
Weather Impact: Confirmed that weather did not affect clinical volumes in Q1.
Confidence in Volume Growth: Management expressed confidence in achieving the 20% volume growth target for the year, supported by improved trends.
MRD Pipeline Priority: MRD testing is now a priority following recent product launches, with plans for a focused push in the near future.
Market Addressability for ChromaSeq: Approximately 50,000 patients identified as potential candidates for the newly launched ChromaSeq assay.

Overall, Caris Life Sciences demonstrated strong financial performance in Q1 2026, with significant revenue growth and strategic advancements in product offerings, while also navigating challenges related to volume expectations and reimbursement concerns.

CAI — Caris Life Sciences, Inc.